PC
ANTH

Palo Capital’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Palo Capital’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,549
Closed -$75K – 156
2015
Q3 		$75K Buy
+1,549
New +$108K 0.07% 131

Other funds holding ANTH

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

Palo Capital's ANTH Position: Q4 2015 in Review

Palo Capital sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q4 2015, closing a stake of 1,549 shares — an estimated $75K sold.

Palo Capital first reported a position in ANTH in Q3 2015 and held it in 1 quarter. The position peaked at $75K in Q3 2015. 86 funds tracked by Wall St. Rank hold ANTH as of Q4 2015.

  • Palo Capital reported no remaining Anthera Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • Palo Capital sold 1,549 Anthera Pharmaceuticals, Inc. shares in Q4 2015, an estimated $75K.
  • Palo Capital first reported a position in Anthera Pharmaceuticals, Inc. in Q3 2015 and held it in 1 quarter.
  • Palo Capital's Anthera Pharmaceuticals, Inc. position peaked at $75K in Q3 2015.
  • 86 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q4 2015.

Based on Palo Capital's 13F filing for Q4 2015, filed 25 Jan 2016.